Analyst: Novo Nordisk's estimated sales growth decrease not as big as expected

A general price squeeze and lower sales in China will be evident in Novo Nordisk's sales growth next year, but the predicted impact is less significant than anticipated, says a Sydbank analyst.

Photo: Novo Nordisk / PR

On Friday, Novo Nordisk reports that global sales growth will be negatively affected by a 3 percent sales growth decrease in 2022 because of a new Chinese insulin tender model, resulting in lower prices and volumes of insulin sold in China.

However, the impact is less pronounced than the market's prediction following Novo Nordisk's previous forecast, which was released in connection with its third quarterly report, assesses Senior Equity Analyst at Sydbank Søren Løntoft Hansen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs